Loading publications…
The last 5 uploaded publications
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
Josep M. Llovet, Catherine E. Willoughby, Amit G. Singal, Tim F. Greten, Mathias Heikenwälder, Hashem B. El–Serag, Richard S. Finn, Scott L. Friedman (2023). Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. Nature Reviews Gastroenterology & Hepatology, 20(8), pp. 487-503, DOI: 10.1038/s41575-023-00754-7.
Article145 days agoMolecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis
Roser Pinyol, Sara Torrecilla, Huan Wang, Carla Montironi, Marta Piqué‐Gili, Miguel Torres‐Martín, Wei Qiang Leow, Catherine E. Willoughby, Pierluigi Ramadori, Carmen Andreu-Oller, Patricia Taik, Youngmin A. Lee, Agrin Moeini, Judit Peix, Suzanne Faure‐Dupuy, Tobias Riedl, Svenja Schuehle, Cláudia P. Oliveira, Venâncio Avancini Ferreira Alves, Paolo Boffetta, Anja Lachenmayer, Stephanie Roessler, Beatriz Mínguez, Peter Schirmacher, Jean‐François Dufour, Swan N. Thung, Helen L. Reeves, Flair José Carrilho, Charissa Chang, Andrew Uzilov, Mathias Heikenwälder, Arun J. Sanyal, Scott L. Friedman, Daniela Sia, Josep M. Llovet (2021). Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. Journal of Hepatology, 75(4), pp. 865-878, DOI: 10.1016/j.jhep.2021.04.049.
Article145 days agoImmunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma
Laura Torrens, Carla Montironi, Marc Puigvehí, Agavni Mesropian, Jack Leslie, Philipp K. Haber, Miho Maeda, Ugne Balaseviciute, Catherine E. Willoughby, Jordi Abril‐Fornaguera, Marta Piqué‐Gili, Miguel Torres‐Martín, Judit Peix, Daniel Geh, Erik Ramón-Gil, Behnam Saberi, Scott L. Friedman, Derek A. Mann, Daniela Sia, Josep M. Llovet (2021). Immunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma. Hepatology, 74(5), pp. 2652-2669, DOI: 10.1002/hep.32023.
Article145 days agoCXCR2 inhibition enables NASH-HCC immunotherapy
Jack Leslie, John B. G. Mackey, Thomas Jamieson, Erik Ramón-Gil, Thomas M. Drake, Frédéric Fercoq, William Clark, Kathryn Gilroy, Ann Hedley, Colin Nixon, Saimir Luli, Maja Laszczewska, Roser Pinyol, Roger Esteban-Fabró, Catherine E. Willoughby, Philipp K. Haber, Carmen Andreu-Oller, Mohammad Rahbari, Chaofan Fan, Dominik Pfister, Shreya Raman, Niall Wilson, Miryam Müller, Amy Collins, Daniel Geh, Andrew Fuller, David McDonald, Gillian Hulme, Andrew Filby, Xabier Cortés-Lavaud, Noha-Ehssan Mohamed, Catriona A. Ford, Ximena L. Raffo Iraolagoitia, Amanda J. McFarlane, Misti McCain, Rachel A. Ridgway, Edward W. Roberts, Simon T. Barry, Gerard J. Graham, Mathias Heikenwälder, Helen L. Reeves, Josep M. Llovet, Leo M. Carlin, Thomas G. Bird, Owen J. Sansom, Derek A. Mann (2022). CXCR2 inhibition enables NASH-HCC immunotherapy. Gut, 71(10), pp. 2093-2106, DOI: 10.1136/gutjnl-2021-326259.
Article145 days agoLiver Injury Increases the Incidence of HCC following AAV Gene Therapy in Mice
Dhwanil A. Dalwadi, Laura Torrens, Jordi Abril‐Fornaguera, Roser Pinyol, Catherine E. Willoughby, Jeffrey Posey, Josep M. Llovet, Christian Lanciault, David W. Russell, Markus Grompe, Willscott E. Naugler (2020). Liver Injury Increases the Incidence of HCC following AAV Gene Therapy in Mice. Molecular Therapy, 29(2), pp. 680-690, DOI: 10.1016/j.ymthe.2020.10.018.
Article145 days ago